Alvotech

Alvotech operates in the biotechnology industry, specifically focusing on the development and manufacturing of biosimilar medicines for the global market. The company's mission is to enhance patient access to proven treatments and contribute to the sustainability of healthcare systems by providing affordable biosimilars. The biosimilar market is characterized by complex, large-molecule biological medicines that are highly similar to existing approved biological reference products, offering a cost-effective alternative once patent exclusivity expires. Developing biosimilars is a capital-intensive and time-consuming endeavor, typically taking six to nine years and costing between $100.0 million to $200.0 million ¹, significantly less than the average originator biologic development cost of over $2.5 billion over 12 years ².

Alvotech's core business model revolves around leveraging its vertically integrated platform to develop and manufacture high-quality biosimilars, which are then commercialized globally through a network of strategic partnerships. The company generates revenue through product sales and license and other revenue, which includes upfront and milestone payments from its commercial partners, as well as royalties on sales. The primary customer segments are the commercialization partners who then market and distribute the biosimilars to healthcare providers and patients in their respective territories. The company's platform is designed for in-house execution of the entire product development and scale-up process, from R&D to cGMP manufacturing, clinical testing, and regulatory approvals.

Alvotech currently has five commercialized products approved in major markets and an additional thirty product candidates in its pipeline. AVT02, a biosimilar to Humira (adalimumab), is approved in the U.S., Canada, UK, and European Economic Area. AVT04, a biosimilar to Stelara (ustekinumab), is approved in the U.S., Canada, UK, European Economic Area, and Japan. AVT05, a biosimilar to Simponi (golimumab), is approved in the UK, European Economic Area, and Japan. AVT06, a biosimilar to Eylea (aflibercept), is approved in the UK, European Economic Area, and Japan. AVT03, a biosimilar to Prolia/Xgeva (denosumab), is approved in the UK, European Economic Area, and Japan. The company's pipeline includes AVT16 and AVT80 (biosimilars to Entyvio), AVT23 (biosimilar to Xolair), AVT29 (biosimilar to Eylea HD), AVT32 (biosimilar to Keytruda), AVT10 (biosimilar to Cimzia), AVT19 (biosimilar to Dupixent), AVT28 (biosimilar to Taltz), AVT34 (biosimilar to Imfinzi), AVT41 (biosimilar to Tremfya), AVT48 (biosimilar to Ilaris), AVT65 (biosimilar to Kesimpta), and AVT87 (biosimilar to Hemlibra).

For the fiscal year ended December 31, 2025, Alvotech reported total product revenue of $276.271 million ³ and license and other revenue of $310.1 million ⁴, resulting in total revenue of $586.371 million. The company achieved a net profit of $27.9 million ⁵ for the year, a significant improvement from net losses of $231.9 million ⁶ in 2024 and $551.7 million ⁷ in 2023. As of December 31, 2025, Alvotech had an accumulated deficit of $2,409.8 million ⁸ and cash and cash equivalents of $172.4 million ⁹. Total outstanding indebtedness stood at $1,299.1 million ¹⁰, comprising $1,031.6 million ¹¹ under the Secured Loan Facility, $96.7 million ¹² under the Senior Term Loan Facility, $68.4 million ¹³ under the 2025 Convertible Bonds, and $102.4 million ¹⁴ in bank loans.

Comparing 2025 to 2024, product revenue increased from $273.472 million ¹⁵ to $276.271 million ³. Geographically, Europe's contribution to product revenue significantly increased from 20.7% ¹⁶ ($56.574 million ¹⁷) in 2024 to 55.1% ¹⁸ ($152.201 million ¹⁹) in 2025. Conversely, the USA's share of product revenue decreased from 71.5% ²⁰ ($195.526 million ²¹) in 2024 to 38.3% ²² ($105.889 million ²³) in 2025. The Rest of World segment saw a slight decline from 7.8% ²⁴ ($21.372 million ²⁵) to 6.6% ²⁶ ($18.181 million ²⁷). The shift from a net loss of $231.9 million ⁶ in 2024 to a net profit of $27.9 million ⁵ in 2025 indicates a notable improvement in profitability.

During 2025, Alvotech received marketing authorizations for AVT03, AVT05, and AVT06 in Japan, the UK, and the European Economic Area. Specifically, the European Commission and MHRA granted marketing authorizations for AVT06 on August 21, 2025, and August 28, 2025, respectively ²⁸. AVT03 received marketing authorization on November 24, 2025 ²⁹. In December 2025, Alvotech and Teva reached a settlement and license agreement with Regeneron Pharmaceuticals Inc. for AVT06, granting a U.S. license entry date in the fourth quarter of 2026 ³⁰. The company also acquired the R&D operations of Xbrane Biopharma AB in 2025, initiating the development of AVT10 (biosimilar to Cimzia) ³¹, and acquired the operations of Ivers Lee in Switzerland for packaging and device assembly ³². A collaboration and license agreement was announced with Dr. Reddy's Laboratories Ltd. in 2025 to co-develop, manufacture, and commercialize AVT32 (biosimilar to Keytruda) for global markets ³³. Financially, Alvotech entered into a $100 million Senior Term Loan Facility maturing in December 2027 ³⁴ and issued $108 million of senior unsecured convertible bonds due 2030 ³⁵ in December 2025.

Alvotech anticipates continued losses for the immediate future, despite reporting a net profit of $27.9 million ⁵ for the year ended December 31, 2025. The company expects substantial increases in expenses as it prepares for and supports the commercial launch of approved products, continues analytical, nonclinical, and clinical development of its product candidates, expands the scope of current clinical studies, and advances programs into more expensive clinical studies. Additional expenses are projected for establishing sales and marketing infrastructure, identifying and developing new biosimilar candidates, making upfront, milestone, royalty, or other payments under license agreements, and creating, maintaining, protecting, expanding, and enforcing its intellectual property portfolio.

A major growth area for Alvotech is the commercialization of its newly approved biosimilars. AVT03, AVT05, and AVT06 have received marketing authorizations in Japan, the UK, and the European Economic Area, with launch activities commencing at the end of 2025 with commercial partners. The settlement and license agreement for AVT06 in the United States grants a license entry date in the fourth quarter of 2026 ³⁰, or potentially earlier under certain circumstances, which represents a significant market opportunity. The company also expects to launch AVT06 in the UK and Canada, as well as Japan (excluding the diabetic macular edema indication) starting May 1 in the European Economic Area and all other countries in the world (other than the U.S.), and from November 1, 2026 in Japan with all approved indications ³⁶.

Another key growth vector is the expansion of its product pipeline and strategic partnerships. The company is advancing AVT16 and AVT80 (biosimilars to Entyvio), AVT23 (biosimilar to Xolair), AVT29 (biosimilar to Eylea HD), AVT32 (biosimilar to Keytruda), and AVT10 (biosimilar to Cimzia), among others, through development. The collaboration with Dr. Reddy's Laboratories for AVT32 aims to jointly develop, manufacture, and commercialize a biosimilar to Keytruda for global markets ³³. The in-licensing of AVT23 from Kashiv Biosciences LLC covers commercialization in the European Union, UK, Australia, Canada, and New Zealand ³⁷, with marketing approval applications pending. These partnerships and pipeline expansion are crucial for broadening Alvotech's global reach and market penetration.

Operationally, Alvotech is focused on strengthening its internal control over financial reporting, having made progress in 2025 but not fully remediating identified material weaknesses related to trained personnel, control execution, documentation, segregation of duties, and IT general controls. The company continues to implement measures to address these weaknesses, including enhancements to control design and execution, improvements to documentation and review processes, strengthened monitoring activities, and ongoing evaluation and refinement of its internal control framework. Capital expenditures for 2025 amounted to $64.5 million ³⁸, primarily for property, plant and equipment, leasehold improvements, lab equipment, and computer equipment in Iceland. The company's manufacturing processes utilize single-use processing technology, relying on external suppliers for components, and is evaluating opportunities for redundancies to mitigate supply chain risks and control costs.

Alvotech's planned capital allocation includes continued significant investment in research and development activities, aiming to offer more affordable biologic medicines globally. The company's capital expenditures for the years ended December 31, 2025, 2024, and 2023 were $64.5 million ³⁸, $53.7 million ³⁹, and $33.2 million ⁴⁰, respectively, primarily for property, plant and equipment, leasehold improvements, lab equipment, and computer equipment in Iceland. The company's financing activities in December 2025, including the $100 million Senior Term Loan Facility ³⁴ and the $108 million ³⁵ 2025 Convertible Bonds, indicate a strategy to manage debt maturities and enhance liquidity.

Management explicitly flagged several structural headwinds and execution risks. The regulatory review and approval processes, particularly with the FDA, EMA, and MHRA, are lengthy, time-consuming, and have uncertain outcomes, as evidenced by the Complete Response Letters received for AVT03, AVT05, and AVT06 due to manufacturing facility deficiencies ⁴¹. Evolving FDA policies on interchangeability may affect market adoption of biosimilars, and the complexity of manufacturing protein-based therapeutics poses challenges in demonstrating biosimilarity and scaling production. The company's reliance on third parties for manufacturing, clinical studies, and commercialization introduces risks related to supply chain disruptions, regulatory compliance, and partner performance.

Geographic, regulatory, and macro factors identified as constraints include the evolving sustainability reporting and due-diligence framework in the European Union, such as the Corporate Sustainability Reporting Directive (CSRD) and EU Taxonomy Regulation, which may require significant investments in compliance. Healthcare cost-containment measures, including the U.S. Inflation Reduction Act, and potential tariffs on imported pharmaceuticals, may reduce the addressable market and affect pricing. International operations expose the company to risks from economic weakness, political instability, differing regulatory requirements, foreign-exchange fluctuations, and trade protection measures.

Alvotech faces material risks across several dimensions. Macroeconomic risks include the potential for significant losses, as the company incurred net losses of $231.9 million ⁶ in 2024 and $551.7 million ⁷ in 2023, with an accumulated deficit of $2,409.8 million ⁸ as of December 31, 2025, and may continue to incur losses for the immediate future. The company has substantial indebtedness of $1,299.1 million ¹⁰ as of December 31, 2025, including a $965.0 million ⁴² Secured Loan Facility and a $100 million ³⁴ Senior Term Loan Facility, which could make it difficult to satisfy debt obligations if cash flow is insufficient. Competitive risks are significant, with numerous large, experienced pharmaceutical and biotechnology companies developing biosimilars, such as Celltrion, Amgen, Samsung Bioepis, Biocon, and Sandoz, who possess greater financial, R&D, manufacturing, and marketing resources. Regulatory risks are highlighted by the Complete Response Letters from the FDA for AVT03, AVT05, and AVT06 due to manufacturing facility deficiencies ⁴¹, which could delay U.S. market entry. Evolving regulatory policies, such as the EU clinical studies Regulation and UK modernization initiatives, introduce uncertainty in development timelines and costs. Geopolitical risks include potential supply chain disruptions from conflicts in the Middle East impacting shipments through the Suez Canal, which could cause delays or unexpected cost increases for materials originating in Asia. Operational risks include reliance on single-source suppliers for critical components, the complexity of manufacturing processes, and the potential for cybersecurity attacks or information security breaches that could disrupt operations or compromise sensitive data.

Management's overall tone emphasizes a strategic focus on leveraging its vertically integrated platform to develop and manufacture high-quality biosimilars and commercialize them through a global network of partners. Despite reporting a net profit of $27.9 million ⁵ for the year ended December 31, 2025, management anticipates continued losses for the immediate future, driven by substantial increases in expenses related to commercial launches and ongoing R&D. A key strategic priority is to resolve the deficiencies identified by the FDA in the Complete Response Letters for AVT03, AVT05, and AVT06, which are related to the Reykjavik manufacturing facility, to enable U.S. market approval. Another priority is the continued expansion and advancement of the product pipeline, including the co-development of AVT32 (biosimilar to Keytruda) with Dr. Reddy's Laboratories and the in-licensing of AVT23 (biosimilar to Xolair) for key markets. Management also stresses the importance of maintaining and strengthening its global network of commercial partnerships to ensure broad market access and optimize commercial opportunities for its approved and pipeline products.